Biocept announces full enrollment in FORESEE trial

Biocept announced the full enrollment of 40 subjects with breast or non-small cell lung cancer, or NSCLC, who have suspicious or confirmed leptomeningeal metastases, or LM, in the feasibility phase of its prospective FORESEE clinical trial. This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians.